ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Zoetis Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$79.59+0.21 (+0.26%)
Close on Oct 19, 2026
- Market cap
- $33.24B
- P/E (TTM)
- 13.1
- Dividend yield
- 2.55%
Share price
−$64.47 (−44.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Zoetis Inc. grew revenue 1.5% to $9.52B over the twelve months to Jun 30, 2026. Free cash flow was $2.32B, up 2.1% from a year earlier.
Revenue
$9.52B
+1.5% vs. a year earlier
Free cash flow
$2.32B
+2.1% vs. a year earlier
EPS, diluted
$6.08
+5.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $33.24B
- P/E ratio
- 13.1
- Price to sales
- 3.49
- Price to book
- 10.56
- Dividend yield
- 2.55%
- Free cash flow yield
- 6.97%
Fundamentals
- Revenue
- $9.52B
- Net income
- $2.62B
- EPS, diluted
- $6.08
- Free cash flow
- $2.32B
- Book value per share
- $7.54
- Diluted shares
- 418M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$9.52B+1.5% YoY
Gross profit
$6.81B+1.8% YoY
Net income
$2.62B+1.0% YoY
EPS, diluted
$6.08+5.6% YoY
Free cash flow
$2.32B+2.1% YoY
Reported periodTrailing twelve months